BioSpace News Archive

Foghorn Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced that the company will present a poster and chair a panel at the American Association for Cancer Research Annual Meeting 2021, which is being held virtually from April 10-15.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that it will present at the Maxim Group Inaugural Emerging Growth Virtual Conference hosted by M-Vest.

Bristol Myers Squibb, the biopharmaceutical company that discovers, develops and delivers innovative medicines to help patients prevail over serious diseases, and Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, are excited to announce that Pierluigi Mantovani of Evolution Devices was chosen as the winner of the Addressing Unmet Needs in MS: An Innovation Challenge.

Endo International plc announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. and Endo U.S. Inc. priced $1.295 billion aggregate principal amount of 6.125% senior secured notes due 2029 at an issue price of $1,000 per $1,000 principal amount in connection with its previously announced private offering, which represents an upsize of $295.0 million over the previously contemplated offering amount.

Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in the Phase III clinical trial of its new global investigational tumor necrosis factor (TNF) receptor-1 fragment-based drug Tanfanercept (HBM9036) for adult patients with moderate-to-severe dry eye disease (DED) in China.

Health Canada is aware of reports of adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine, and would like to reassure Canadians that the benefits of the vaccine continue to outweigh its risks.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share

NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing trigeminal nerve stimulation technology to treat neurological and neuropsychiatric disorders, announced that the following patents have issued or received notices of allowance in Canada and Japan:

Invacare Corporation priced $110 million aggregate principal amount of 4.25% convertible senior notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Gregory Harper, the company’s Vice President, R&D and Clinical, will retire effective March 31, 2021.